Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.

Lyritis G, Marin F, Barker C, Pfeifer M, Farrerons J, Brixen K, del Pino J, Keen R, Nickelsen TN

Current medical research and opinion1 Aug 2010Cited by 32 (Europe PMC)

PMID20482322DOI10.1185/03007995.2010.488516PepBankPUB-20482322

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis after 12 months of teriparatide, back pain changes from randomisation to 18 or 24 months did not differ between the randomised groups.
In plain wordsAfter 12 months of teriparatide, back pain changes did not differ between the groups randomised to teriparatide, raloxifene or no active treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBack pain between groups after randomisation
Study
n = 507
Comparator
Raloxifene or no active treatment
Outcome group
Pain · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Source sentences
Summary
There were no between-group differences from randomization to 18 or 24 months.
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, controlled, randomised, open-label, 2-year study enrolled 868 postmenopausal women with osteoporosis and a recent fragility fracture.
Summary · context
After 12 months of teriparatide (20 microg/day), 507 patients were randomised to further teriparatide (n = 305), raloxifene 60 mg/day (n = 100), or no active treatment (n = 102) for another 12 months (substudy 1); in substudy 2, 199 patients continued teriparatide.
Summary · context
All received calcium and vitamin D supplementation.
Report a problemFND-2048232203
02HumanNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis, back pain decreased by 11.5 mm from baseline during the first year of teriparatide.
In plain wordsIn women with osteoporosis, back pain decreased from baseline during the first year of teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain during initial treatment
Study
n = 868
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Studied dose
20 microg/day · 12 monthsAs given in this study (human).
Measurements
Back pain change
−11.5 mm
year 1
Source sentences
Summary
During year 1, back pain decreased from a mean (SD) of 48.9 mm (24.0) at baseline by 11.5 mm (p < 0.001) in the total study population.
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, controlled, randomised, open-label, 2-year study enrolled 868 postmenopausal women with osteoporosis and a recent fragility fracture.
Summary · context
After 12 months of teriparatide (20 microg/day), 507 patients were randomised to further teriparatide (n = 305), raloxifene 60 mg/day (n = 100), or no active treatment (n = 102) for another 12 months (substudy 1); in substudy 2, 199 patients continued teriparatide.
Summary · context
All received calcium and vitamin D supplementation.
Report a problemFND-2048232201
03HumanNon-randomized trialEfficacy outcome
In women continuing teriparatide, back pain changed by -2.2 mm from month 12 to 24, without statistical significance.
In plain wordsIn women continuing teriparatide, back pain did not change significantly from month 12 to 24.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBack pain during continued treatment
Study
n = 305
Comparator
Month 12
Outcome group
Pain · Musculoskeletal
Studied dose
20 microg/day · 24 monthsAs given in this study (human).
Measurements
Back pain change
−2.2 mm
month 12 to 24
Source sentences
Summary
In substudy 1, mean change in back pain from month 12 (randomisation) to 24 months was -2.2, -4.4 and +0.7 mm in the teriparatide (p = 0.076), raloxifene (p = 0.041), and no active treatment groups (p = 0.751).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, controlled, randomised, open-label, 2-year study enrolled 868 postmenopausal women with osteoporosis and a recent fragility fracture.
Summary · context
After 12 months of teriparatide (20 microg/day), 507 patients were randomised to further teriparatide (n = 305), raloxifene 60 mg/day (n = 100), or no active treatment (n = 102) for another 12 months (substudy 1); in substudy 2, 199 patients continued teriparatide.
Summary · context
All received calcium and vitamin D supplementation.
Report a problemFND-2048232202
04HumanNon-randomized trialEfficacy outcome
In women excluding those with low baseline back pain, back pain decreased by 3.9 mm from randomisation to endpoint in the teriparatide group.
In plain wordsIn women without low baseline pain, back pain decreased from randomisation to endpoint in the teriparatide group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain excluding low baseline pain
Study
n: not reported in source
Comparator
Randomisation
Outcome group
Pain · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Measurements
Back pain change
−3.9 mm
sensitivity analysis
Source sentences
Summary
In a sensitivity analysis excluding patients with low baseline back pain (VAS < 30 mm), mean change from randomisation to endpoint was significant for teriparatide (-3.9 mm, p = 0.006) and raloxifene (-6.3 mm, p = 0.018) groups.
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, controlled, randomised, open-label, 2-year study enrolled 868 postmenopausal women with osteoporosis and a recent fragility fracture.
Summary · context
After 12 months of teriparatide (20 microg/day), 507 patients were randomised to further teriparatide (n = 305), raloxifene 60 mg/day (n = 100), or no active treatment (n = 102) for another 12 months (substudy 1); in substudy 2, 199 patients continued teriparatide.
Summary · context
All received calcium and vitamin D supplementation.
Report a problemFND-2048232205
05HumanNon-randomized trialEfficacy outcome
In teriparatide-treated women, back pain decreased significantly in subgroups with and without mild or severe baseline back pain.
In plain wordsIn women receiving teriparatide, pain decreased from baseline in all reported baseline pain severity subgroups.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain across baseline severity subgroups
Study
n: not reported in source
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Studied dose
20 microg/day · 24 monthsAs given in this study (human).
Source sentences
Summary
Those with and without mild back pain (>or=30 mm), and those with and without severe back pain (>or=60 mm) at baseline all had a statistically significant reduction in back pain after 24 months (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, controlled, randomised, open-label, 2-year study enrolled 868 postmenopausal women with osteoporosis and a recent fragility fracture.
Summary · context
After 12 months of teriparatide (20 microg/day), 507 patients were randomised to further teriparatide (n = 305), raloxifene 60 mg/day (n = 100), or no active treatment (n = 102) for another 12 months (substudy 1); in substudy 2, 199 patients continued teriparatide.
Summary · context
All received calcium and vitamin D supplementation.
Report a problemFND-2048232207

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
Among teriparatide-treated women, a recent vertebral fracture was linked to a greater back pain decrease than no recent fracture.
In plain wordsAmong teriparatide-treated women, recent vertebral fracture was linked to greater pain reduction than no recent fracture.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain response by recent vertebral fracture
Study
n = 503
Comparator
No recent vertebral fracture
Outcome group
Pain · Musculoskeletal
Source sentences
Summary
Subgroup analyses of 503 patients who received teriparatide for up to 2 years showed that patients with a recent vertebral fracture had a greater decrease in back pain than those without (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, controlled, randomised, open-label, 2-year study enrolled 868 postmenopausal women with osteoporosis and a recent fragility fracture.
Summary · context
After 12 months of teriparatide (20 microg/day), 507 patients were randomised to further teriparatide (n = 305), raloxifene 60 mg/day (n = 100), or no active treatment (n = 102) for another 12 months (substudy 1); in substudy 2, 199 patients continued teriparatide.
Summary · context
All received calcium and vitamin D supplementation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2048232206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.